Having placed leaders into roles like this repeatedly, we wrote this to give a practitioner’s view rather than generic advice. A MedTech startup scaling after a Series B faces a distinctive leadership challenge: it must add executive talent that can take the company from promising to commercial-stage, without breaking the culture or outrunning its regulatory and clinical realities. Post-Series B hiring is about bringing in leaders who can scale a regulated business, not just any impressive executives, and the search strategy must reflect that.
Key Takeaways
- Post-Series B MedTech hiring must add commercial-scale leadership.
- Leaders must be able to scale a regulated, clinical business specifically.
- Match executives to the company’s stage and regulatory reality.
- Move deliberately, since a bad senior hire is costly at this stage.
- Build leadership that can take the company toward commercialization.
The Post-Series B Inflection
A Series B typically signals that a MedTech company has moved past early proof and is scaling toward commercialization, and this inflection changes the leadership it needs. The company must build out executive functions, commercial, operations, regulatory, quality, that can carry it from a promising technology to a scaled, commercial-stage business, all within the regulatory and clinical constraints medical devices carry. This is a specific hiring challenge: adding leaders who can scale a regulated MedTech business, not just impressive executives from unrelated contexts. The search strategy must target leaders who can operate at the company’s next stage while respecting its regulatory and clinical realities.
Hiring for Scale Within Regulatory Reality
The leaders a scaling MedTech company needs must be able to scale, build repeatable commercial and operational capability, grow teams, and add rigor, but within the regulatory and clinical framework medical devices demand. A commercial leader who can scale a consumer business but does not understand regulated MedTech commercialization may misfire; a leader who understands the regulatory and clinical reality and can still drive commercial scale is far more valuable. The search should target leaders with genuine experience scaling regulated MedTech businesses, or at least deep understanding of the constraints, since scaling a device company is not the same as scaling an unregulated one.
Matching Executives to Stage
Post-Series B is a specific stage, past early startup, not yet large-company, and executives must fit it. A large-company executive accustomed to resources and structure may struggle in a still-lean scaling company, while an early-startup builder may lack the scaling capability the company now needs. The search should match executives to the post-Series B scaling stage: leaders who can build and scale functions in a growing but still-resourced-constrained MedTech company, and who fit its regulatory and clinical context. Matching to stage, not just hiring impressive names, is central, since the wrong-stage executive, however capable elsewhere, tends to misfit a scaling MedTech company.
What This Looks Like in Practice
A scaling MedTech company targets leaders who can scale a regulated business at the post-Series B stage: it seeks executives with genuine experience scaling MedTech or regulated businesses, matches them to the company’s specific stage and regulatory reality, and moves deliberately given the cost of a bad senior hire. It builds toward commercialization. It does not simply hire impressive executives from unrelated or unregulated contexts, or mismatch large-company or early-startup leaders to a scaling MedTech company.
The Mistake Employers Keep Making
The most common mistake is hiring impressive executives whose experience does not fit a scaling regulated MedTech business, a commercial leader from an unregulated industry, or a large-company executive who cannot operate lean, assuming their pedigree will translate. It often does not: scaling a regulated device company is specific, and the wrong-context or wrong-stage executive tends to misfire. The company mistakes general impressiveness for fit with a scaling MedTech business, and pays for it with a costly senior mishire.
Matching Executives to the Post-Series B Stage
| Executive Profile | Fit for Scaling MedTech |
|---|---|
| Regulated MedTech scaler | Strong, understands the specific challenge |
| Unregulated-industry commercial leader | Risky without MedTech grasp |
| Large-company executive | May struggle with lean scaling |
| Early-startup builder | May lack scaling capability |
| Right fit | Can scale a regulated business at this stage |
The Bottom Line
A MedTech startup scaling post-Series B must add leaders who can scale a regulated, clinical business at its specific stage, so target executives with genuine regulated-MedTech scaling experience matched to the company’s stage and regulatory reality, and move deliberately, rather than hiring impressive executives whose experience does not fit a scaling device company. Hire for the specific demands of the situation, and the rest of the leadership equation gets easier.
Related Reading
For more, see Building a Leadership Team for a Medical Device Company Pre-IPO, How to Recruit Top Talent in a Competitive MedTech Market, Why MedTech Companies Need Specialized Executive Recruiters.
Frequently Asked Questions
- Q: What changes at the post-Series B stage?
- A: The company scales toward commercialization, so it must build out executive functions, commercial, operations, regulatory, quality, that can carry it from promising technology to a scaled, commercial-stage business.
- Q: What kind of leaders does a scaling MedTech company need?
- A: Leaders who can scale a regulated, clinical business, building repeatable commercial and operational capability within the regulatory framework, not just impressive executives from unrelated contexts.
- Q: Why match executives to stage?
- A: Because a large-company executive may struggle in a lean scaling company and an early-startup builder may lack scaling capability, so leaders must fit the specific post-Series B stage.
- Q: Can a commercial leader from another industry work?
- A: Only if they genuinely understand regulated MedTech commercialization; a leader who scaled an unregulated business may misjudge the regulatory and clinical constraints.
- Q: Why move deliberately at this stage?
- A: Because a bad senior hire is costly for a scaling company with limited resources and time, so the search should be careful and well-matched rather than rushed.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
